Kairos Pharma acquires CL-741 oncology asset from Celyn Therapeutics

Kairos Pharma announced a strategic acquisition of worldwide rights to CL-741, a Phase 1-ready c-MET kinase inhibitor for NSCLC and gastric cancers, targeting a $16.2B EGFR-mutant lung cancer market. The company plans Phase 1 initiation and multiple clinical milestones through 2026 while maintaining a lean operation with $8M+ in non-dilutive funding.